Stock Analysis on Net

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

Analysis of Solvency Ratios
Quarterly Data

Microsoft Excel

Solvency Ratios (Summary)

Regeneron Pharmaceuticals Inc., solvency ratios (quarterly data)

Microsoft Excel
Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Debt Ratios
Debt to equity 0.09 0.10 0.10 0.10 0.11 0.11 0.11 0.12 0.13 0.13 0.14 0.14 0.16 0.18 0.23 0.24 0.27 0.24 0.06 0.06 0.07 0.07 0.08
Debt to capital 0.08 0.09 0.09 0.09 0.10 0.10 0.10 0.11 0.11 0.12 0.12 0.13 0.14 0.15 0.18 0.20 0.21 0.20 0.06 0.06 0.06 0.07 0.07
Debt to assets 0.07 0.07 0.08 0.08 0.08 0.09 0.09 0.09 0.10 0.10 0.10 0.11 0.11 0.13 0.15 0.16 0.17 0.15 0.05 0.05 0.05 0.05 0.06
Financial leverage 1.28 1.28 1.27 1.27 1.29 1.28 1.28 1.29 1.29 1.32 1.32 1.36 1.37 1.42 1.48 1.56 1.59 1.59 1.30 1.34 1.33 1.35 1.36
Coverage Ratios
Interest coverage 79.88 69.47 57.85 58.52 61.70 69.61 73.97 82.80 108.62 116.35 163.24 163.75 139.74 104.12 68.20 67.97 72.22 108.12 90.22 81.43

Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Solvency ratio Description The company
Debt to equity ratio A solvency ratio calculated as total debt divided by total shareholders’ equity. Regeneron Pharmaceuticals Inc. debt to equity ratio improved from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024.
Debt to capital ratio A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. Regeneron Pharmaceuticals Inc. debt to capital ratio improved from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024.
Debt to assets ratio A solvency ratio calculated as total debt divided by total assets. Regeneron Pharmaceuticals Inc. debt to assets ratio improved from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024.
Financial leverage ratio A solvency ratio calculated as total assets divided by total shareholders’ equity. Regeneron Pharmaceuticals Inc. financial leverage ratio increased from Q1 2024 to Q2 2024 but then slightly decreased from Q2 2024 to Q3 2024.

Solvency ratio Description The company
Interest coverage ratio A solvency ratio calculated as EBIT divided by interest payments. Regeneron Pharmaceuticals Inc. interest coverage ratio improved from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024.

Debt to Equity

Regeneron Pharmaceuticals Inc., debt to equity calculation (quarterly data)

Microsoft Excel
Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Selected Financial Data (US$ in thousands)
Debt 1,500,000
Finance lease liabilities, current portion 719,700 719,000 718,400 717,800
Long-term debt 1,984,000 1,983,600 1,983,300 1,982,900 1,982,600 1,982,200 1,981,800 1,981,400 1,981,100 1,980,700 1,980,400 1,980,000 1,979,600 1,979,200 1,978,900 1,978,500 1,978,300
Finance lease liabilities, excluding current portion 720,000 720,000 720,000 720,000 720,000 720,000 720,000 720,000 720,000 720,000 720,000 717,200 716,500 715,900 715,200 713,900 712,700 711,300 709,900
Total debt 2,704,000 2,703,600 2,703,300 2,702,900 2,702,600 2,702,200 2,701,800 2,701,400 2,701,100 2,700,700 2,700,400 2,699,700 2,698,600 2,697,600 2,696,700 2,695,700 2,694,800 2,215,900 715,200 713,900 712,700 711,300 709,900
 
Stockholders’ equity 29,325,900 28,205,800 26,991,100 25,973,100 24,904,400 24,017,900 23,495,200 22,664,000 21,438,800 20,687,800 19,914,700 18,768,800 17,258,000 15,127,300 11,977,000 11,025,300 10,125,500 9,057,400 12,133,000 11,089,700 10,504,400 9,755,900 9,444,700
Solvency Ratio
Debt to equity1 0.09 0.10 0.10 0.10 0.11 0.11 0.11 0.12 0.13 0.13 0.14 0.14 0.16 0.18 0.23 0.24 0.27 0.24 0.06 0.06 0.07 0.07 0.08
Benchmarks
Debt to Equity, Competitors2
AbbVie Inc. 11.78 10.42 9.24 5.73 5.02 4.74 4.68 3.67 4.35 4.98 4.51 4.98 5.96 6.53 6.24 6.58 5.70 5.94
Amgen Inc. 8.02 10.57 12.75 10.37 7.90 9.08 11.52 10.64 10.60 15.10 40.23 4.97 4.57 3.98 3.50 3.51 3.13 3.21 3.36 3.09 2.73 2.84 3.05
Bristol-Myers Squibb Co. 2.90 3.08 3.38 1.35 1.30 1.18 1.19 1.27 1.20 1.29 1.42 1.24 1.20 1.23 1.23 1.34 0.90 0.95 0.94 0.91 1.41 1.56 0.40
Danaher Corp. 0.34 0.34 0.34 0.34 0.42 0.38 0.39 0.39 0.41 0.43 0.47 0.49 0.54 0.48 0.50 0.53 0.57 0.62 0.84 0.72 0.54 0.32 0.30
Eli Lilly & Co. 2.19 2.13 2.05 2.34 1.80 1.70 1.69 1.52 1.58 1.97 1.77 1.88 2.20 2.56 2.35 2.94 3.51 3.99 5.60 5.88 4.50 5.68 6.44
Gilead Sciences Inc. 1.28 1.44 1.09 1.12 1.19 1.20 1.19 1.20 1.30 1.32 1.27 1.29 1.53 1.59 1.73 1.68 1.34 1.09 1.09 1.19 1.15 1.21
Johnson & Johnson 0.51 0.58 0.48 0.43 0.42 0.61 0.75 0.52 0.43 0.43 0.44 0.46 0.48 0.48 0.51 0.56 0.59 0.48 0.45 0.47 0.50 0.48 0.50
Merck & Co. Inc. 0.87 0.85 0.93 0.85 0.95 0.66 0.67 0.68 0.73 0.78 0.87 0.74 0.80 1.16 1.26 0.98 1.12 1.07 1.02 0.97 0.96 0.94
Moderna Inc. 0.05 0.04 0.04 0.04 0.05 0.04 0.05 0.05 0.04 0.04 0.04 0.02 0.05 0.04 0.04 0.04 0.02 0.02 0.03 0.04 0.03 0.03
Pfizer Inc. 0.73 0.79 0.75 0.81 0.66 0.66 0.36 0.37 0.40 0.46 0.44 0.50 0.53 0.56 0.58 0.63 0.97 0.99 0.80 0.83 0.81 0.78 0.77
Thermo Fisher Scientific Inc. 0.72 0.75 0.78 0.75 0.78 0.78 0.83 0.78 0.67 0.72 0.81 0.85 0.56 0.51 0.53 0.63 0.66 0.71 0.70 0.60 0.58 0.66 0.66

Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Q3 2024 Calculation
Debt to equity = Total debt ÷ Stockholders’ equity
= 2,704,000 ÷ 29,325,900 = 0.09

2 Click competitor name to see calculations.

Solvency ratio Description The company
Debt to equity ratio A solvency ratio calculated as total debt divided by total shareholders’ equity. Regeneron Pharmaceuticals Inc. debt to equity ratio improved from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024.

Debt to Capital

Regeneron Pharmaceuticals Inc., debt to capital calculation (quarterly data)

Microsoft Excel
Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Selected Financial Data (US$ in thousands)
Debt 1,500,000
Finance lease liabilities, current portion 719,700 719,000 718,400 717,800
Long-term debt 1,984,000 1,983,600 1,983,300 1,982,900 1,982,600 1,982,200 1,981,800 1,981,400 1,981,100 1,980,700 1,980,400 1,980,000 1,979,600 1,979,200 1,978,900 1,978,500 1,978,300
Finance lease liabilities, excluding current portion 720,000 720,000 720,000 720,000 720,000 720,000 720,000 720,000 720,000 720,000 720,000 717,200 716,500 715,900 715,200 713,900 712,700 711,300 709,900
Total debt 2,704,000 2,703,600 2,703,300 2,702,900 2,702,600 2,702,200 2,701,800 2,701,400 2,701,100 2,700,700 2,700,400 2,699,700 2,698,600 2,697,600 2,696,700 2,695,700 2,694,800 2,215,900 715,200 713,900 712,700 711,300 709,900
Stockholders’ equity 29,325,900 28,205,800 26,991,100 25,973,100 24,904,400 24,017,900 23,495,200 22,664,000 21,438,800 20,687,800 19,914,700 18,768,800 17,258,000 15,127,300 11,977,000 11,025,300 10,125,500 9,057,400 12,133,000 11,089,700 10,504,400 9,755,900 9,444,700
Total capital 32,029,900 30,909,400 29,694,400 28,676,000 27,607,000 26,720,100 26,197,000 25,365,400 24,139,900 23,388,500 22,615,100 21,468,500 19,956,600 17,824,900 14,673,700 13,721,000 12,820,300 11,273,300 12,848,200 11,803,600 11,217,100 10,467,200 10,154,600
Solvency Ratio
Debt to capital1 0.08 0.09 0.09 0.09 0.10 0.10 0.10 0.11 0.11 0.12 0.12 0.13 0.14 0.15 0.18 0.20 0.21 0.20 0.06 0.06 0.06 0.07 0.07
Benchmarks
Debt to Capital, Competitors2
AbbVie Inc. 0.92 0.91 0.90 0.85 0.83 0.83 0.82 0.79 0.81 0.83 0.82 0.83 0.86 0.87 0.86 0.87 0.85 0.86 1.12 1.14 1.27 1.30 1.27
Amgen Inc. 0.89 0.91 0.93 0.91 0.89 0.90 0.92 0.91 0.91 0.94 0.98 0.83 0.82 0.80 0.78 0.78 0.76 0.76 0.77 0.76 0.73 0.74 0.75
Bristol-Myers Squibb Co. 0.74 0.75 0.77 0.57 0.56 0.54 0.54 0.56 0.54 0.56 0.59 0.55 0.55 0.55 0.55 0.57 0.47 0.49 0.48 0.48 0.59 0.61 0.28
Danaher Corp. 0.25 0.25 0.25 0.26 0.30 0.28 0.28 0.28 0.29 0.30 0.32 0.33 0.35 0.32 0.33 0.35 0.37 0.38 0.46 0.42 0.35 0.24 0.23
Eli Lilly & Co. 0.69 0.68 0.67 0.70 0.64 0.63 0.63 0.60 0.61 0.66 0.64 0.65 0.69 0.72 0.70 0.75 0.78 0.80 0.85 0.85 0.82 0.85 0.87
Gilead Sciences Inc. 0.56 0.59 0.52 0.53 0.54 0.55 0.54 0.54 0.56 0.57 0.56 0.56 0.60 0.61 0.63 0.63 0.57 0.52 0.52 0.54 0.54 0.55
Johnson & Johnson 0.34 0.37 0.32 0.30 0.30 0.38 0.43 0.34 0.30 0.30 0.31 0.31 0.33 0.32 0.34 0.36 0.37 0.33 0.31 0.32 0.33 0.33 0.33
Merck & Co. Inc. 0.46 0.46 0.48 0.46 0.49 0.40 0.40 0.41 0.42 0.44 0.46 0.42 0.44 0.54 0.56 0.50 0.53 0.52 0.50 0.49 0.49 0.48
Moderna Inc. 0.05 0.04 0.04 0.04 0.05 0.04 0.05 0.05 0.03 0.04 0.04 0.02 0.05 0.03 0.04 0.04 0.02 0.02 0.03 0.04 0.03 0.03
Pfizer Inc. 0.42 0.44 0.43 0.45 0.40 0.40 0.26 0.27 0.28 0.32 0.31 0.33 0.35 0.36 0.37 0.39 0.49 0.50 0.45 0.45 0.45 0.44 0.43
Thermo Fisher Scientific Inc. 0.42 0.43 0.44 0.43 0.44 0.44 0.45 0.44 0.40 0.42 0.45 0.46 0.36 0.34 0.35 0.39 0.40 0.42 0.41 0.37 0.37 0.40 0.40

Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Q3 2024 Calculation
Debt to capital = Total debt ÷ Total capital
= 2,704,000 ÷ 32,029,900 = 0.08

2 Click competitor name to see calculations.

Solvency ratio Description The company
Debt to capital ratio A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. Regeneron Pharmaceuticals Inc. debt to capital ratio improved from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024.

Debt to Assets

Regeneron Pharmaceuticals Inc., debt to assets calculation (quarterly data)

Microsoft Excel
Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Selected Financial Data (US$ in thousands)
Debt 1,500,000
Finance lease liabilities, current portion 719,700 719,000 718,400 717,800
Long-term debt 1,984,000 1,983,600 1,983,300 1,982,900 1,982,600 1,982,200 1,981,800 1,981,400 1,981,100 1,980,700 1,980,400 1,980,000 1,979,600 1,979,200 1,978,900 1,978,500 1,978,300
Finance lease liabilities, excluding current portion 720,000 720,000 720,000 720,000 720,000 720,000 720,000 720,000 720,000 720,000 720,000 717,200 716,500 715,900 715,200 713,900 712,700 711,300 709,900
Total debt 2,704,000 2,703,600 2,703,300 2,702,900 2,702,600 2,702,200 2,701,800 2,701,400 2,701,100 2,700,700 2,700,400 2,699,700 2,698,600 2,697,600 2,696,700 2,695,700 2,694,800 2,215,900 715,200 713,900 712,700 711,300 709,900
 
Total assets 37,441,900 36,086,800 34,369,600 33,080,200 32,163,300 30,657,500 30,059,900 29,214,500 27,677,800 27,205,800 26,348,700 25,434,800 23,671,500 21,485,900 17,772,200 17,163,300 16,084,000 14,428,700 15,757,500 14,805,200 13,939,300 13,173,600 12,854,800
Solvency Ratio
Debt to assets1 0.07 0.07 0.08 0.08 0.08 0.09 0.09 0.09 0.10 0.10 0.10 0.11 0.11 0.13 0.15 0.16 0.17 0.15 0.05 0.05 0.05 0.05 0.06
Benchmarks
Debt to Assets, Competitors2
AbbVie Inc. 0.50 0.50 0.50 0.44 0.45 0.45 0.46 0.46 0.49 0.51 0.51 0.52 0.54 0.56 0.57 0.57 0.58 0.58 0.74 0.75 0.65 0.65 0.65
Amgen Inc. 0.66 0.69 0.69 0.67 0.67 0.68 0.69 0.60 0.61 0.62 0.62 0.54 0.58 0.55 0.52 0.52 0.53 0.53 0.52 0.50 0.50 0.52 0.52
Bristol-Myers Squibb Co. 0.53 0.55 0.56 0.42 0.41 0.40 0.40 0.41 0.40 0.42 0.44 0.41 0.40 0.41 0.41 0.43 0.36 0.36 0.36 0.36 0.43 0.45 0.17
Danaher Corp. 0.22 0.22 0.22 0.22 0.25 0.23 0.23 0.23 0.24 0.25 0.26 0.27 0.29 0.26 0.27 0.28 0.30 0.31 0.38 0.35 0.29 0.19 0.18
Eli Lilly & Co. 0.41 0.40 0.41 0.39 0.35 0.34 0.36 0.33 0.33 0.36 0.35 0.35 0.35 0.35 0.35 0.36 0.39 0.39 0.42 0.39 0.40 0.41 0.42
Gilead Sciences Inc. 0.44 0.45 0.40 0.40 0.40 0.41 0.40 0.40 0.42 0.42 0.39 0.41 0.44 0.45 0.46 0.48 0.43 0.40 0.40 0.42 0.41 0.42
Johnson & Johnson 0.20 0.23 0.20 0.18 0.18 0.24 0.27 0.21 0.18 0.18 0.19 0.19 0.19 0.19 0.19 0.20 0.22 0.19 0.18 0.18 0.19 0.19 0.20
Merck & Co. Inc. 0.34 0.32 0.33 0.33 0.35 0.29 0.28 0.28 0.30 0.30 0.31 0.28 0.29 0.34 0.35 0.32 0.34 0.33 0.31 0.31 0.32 0.31
Moderna Inc. 0.04 0.03 0.03 0.03 0.04 0.03 0.04 0.04 0.02 0.02 0.02 0.01 0.02 0.01 0.01 0.02 0.02 0.02 0.02 0.03 0.03 0.02
Pfizer Inc. 0.31 0.32 0.31 0.32 0.30 0.30 0.18 0.18 0.19 0.21 0.20 0.21 0.22 0.23 0.25 0.26 0.35 0.36 0.31 0.31 0.31 0.30 0.29
Thermo Fisher Scientific Inc. 0.35 0.36 0.37 0.35 0.36 0.36 0.37 0.35 0.32 0.33 0.36 0.37 0.29 0.28 0.28 0.31 0.33 0.35 0.34 0.30 0.30 0.33 0.33

Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Q3 2024 Calculation
Debt to assets = Total debt ÷ Total assets
= 2,704,000 ÷ 37,441,900 = 0.07

2 Click competitor name to see calculations.

Solvency ratio Description The company
Debt to assets ratio A solvency ratio calculated as total debt divided by total assets. Regeneron Pharmaceuticals Inc. debt to assets ratio improved from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024.

Financial Leverage

Regeneron Pharmaceuticals Inc., financial leverage calculation (quarterly data)

Microsoft Excel
Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Selected Financial Data (US$ in thousands)
Total assets 37,441,900 36,086,800 34,369,600 33,080,200 32,163,300 30,657,500 30,059,900 29,214,500 27,677,800 27,205,800 26,348,700 25,434,800 23,671,500 21,485,900 17,772,200 17,163,300 16,084,000 14,428,700 15,757,500 14,805,200 13,939,300 13,173,600 12,854,800
Stockholders’ equity 29,325,900 28,205,800 26,991,100 25,973,100 24,904,400 24,017,900 23,495,200 22,664,000 21,438,800 20,687,800 19,914,700 18,768,800 17,258,000 15,127,300 11,977,000 11,025,300 10,125,500 9,057,400 12,133,000 11,089,700 10,504,400 9,755,900 9,444,700
Solvency Ratio
Financial leverage1 1.28 1.28 1.27 1.27 1.29 1.28 1.28 1.29 1.29 1.32 1.32 1.36 1.37 1.42 1.48 1.56 1.59 1.59 1.30 1.34 1.33 1.35 1.36
Benchmarks
Financial Leverage, Competitors2
AbbVie Inc. 23.78 20.94 18.59 13.00 11.26 10.52 10.14 8.04 8.84 9.77 8.80 9.51 10.99 11.77 10.98 11.51 9.80 10.17
Amgen Inc. 12.07 15.34 18.51 15.59 11.83 13.31 16.59 17.79 17.44 24.51 64.62 9.13 7.91 7.25 6.70 6.69 5.90 6.10 6.50 6.17 5.45 5.50 5.91
Bristol-Myers Squibb Co. 5.46 5.56 6.01 3.23 3.15 2.92 2.96 3.12 3.01 3.08 3.26 3.04 2.98 3.01 2.99 3.13 2.50 2.61 2.59 2.52 3.25 3.44 2.29
Danaher Corp. 1.57 1.57 1.56 1.58 1.67 1.64 1.65 1.68 1.72 1.76 1.80 1.84 1.90 1.82 1.87 1.92 1.92 1.97 2.22 2.05 1.89 1.66 1.64
Eli Lilly & Co. 5.31 5.30 4.99 5.94 5.16 4.95 4.75 4.65 4.71 5.51 5.03 5.44 6.21 7.42 6.79 8.27 9.10 10.25 13.35 15.07 11.20 13.91 15.32
Gilead Sciences Inc. 2.93 3.21 2.72 2.80 2.95 2.95 2.97 2.97 3.11 3.17 3.23 3.13 3.45 3.56 3.76 3.49 3.10 2.71 2.74 2.87 2.79 2.86
Johnson & Johnson 2.54 2.53 2.46 2.44 2.33 2.55 2.77 2.44 2.35 2.33 2.39 2.46 2.55 2.54 2.62 2.76 2.65 2.51 2.53 2.65 2.67 2.55 2.54
Merck & Co. Inc. 2.58 2.62 2.84 2.59 2.70 2.30 2.37 2.41 2.48 2.61 2.77 2.61 2.72 3.37 3.62 3.08 3.28 3.24 3.26 3.10 3.04 2.99
Moderna Inc. 1.34 1.31 1.33 1.45 1.29 1.28 1.35 1.45 1.45 1.62 1.74 2.07 2.41 3.31 2.86 1.69 1.18 1.26 1.35 1.27 1.26 1.25
Pfizer Inc. 2.38 2.47 2.40 2.54 2.22 2.22 1.94 2.06 2.10 2.24 2.23 2.35 2.37 2.43 2.31 2.44 2.74 2.77 2.56 2.65 2.62 2.62 2.64
Thermo Fisher Scientific Inc. 2.05 2.08 2.13 2.11 2.14 2.15 2.24 2.21 2.08 2.14 2.26 2.33 1.90 1.84 1.88 2.00 2.01 2.06 2.05 1.97 1.93 2.02 2.01

Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Q3 2024 Calculation
Financial leverage = Total assets ÷ Stockholders’ equity
= 37,441,900 ÷ 29,325,900 = 1.28

2 Click competitor name to see calculations.

Solvency ratio Description The company
Financial leverage ratio A solvency ratio calculated as total assets divided by total shareholders’ equity. Regeneron Pharmaceuticals Inc. financial leverage ratio increased from Q1 2024 to Q2 2024 but then slightly decreased from Q2 2024 to Q3 2024.

Interest Coverage

Regeneron Pharmaceuticals Inc., interest coverage calculation (quarterly data)

Microsoft Excel
Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Selected Financial Data (US$ in thousands)
Net income 1,340,600 1,432,300 722,000 1,159,600 1,007,800 968,400 817,800 1,197,100 1,315,700 852,100 973,500 2,229,000 1,632,200 3,098,900 1,115,200 1,149,200 842,100 897,300 624,600 792,000 669,600 193,100 461,100
Add: Income tax expense 152,400 195,800 (21,300) (12,000) 103,000 114,500 40,200 127,600 194,100 111,100 87,600 274,400 184,400 653,900 137,800 75,400 156,200 21,600 44,000 97,800 98,900 31,600 85,000
Add: Interest expense 13,800 14,800 16,100 18,300 17,800 18,900 18,000 17,400 15,300 13,100 13,600 14,100 14,200 14,400 14,600 14,800 26,300 9,700 6,100 6,700 7,800 8,000 7,700
Earnings before interest and tax (EBIT) 1,506,800 1,642,900 716,800 1,165,900 1,128,600 1,101,800 876,000 1,342,100 1,525,100 976,300 1,074,700 2,517,500 1,830,800 3,767,200 1,267,600 1,239,400 1,024,600 928,600 674,700 896,500 776,300 232,700 553,800
Solvency Ratio
Interest coverage1 79.88 69.47 57.85 58.52 61.70 69.61 73.97 82.80 108.62 116.35 163.24 163.75 139.74 104.12 68.20 67.97 72.22 108.12 90.22 81.43
Benchmarks
Interest Coverage, Competitors2
Amgen Inc. 2.45 2.10 2.38 3.73 4.54 5.43 6.51 6.22 6.83 6.97 6.40 6.60 6.46 6.48 7.64 7.44 7.62 7.62 7.85 8.09
Danaher Corp. 16.11 17.61 17.81 18.64 23.66 29.65 35.60 40.30 41.32 35.26 33.54 32.92 28.74 25.87 21.54 17.35 16.90 20.00 25.33 31.44
Gilead Sciences Inc. 2.58 2.11 8.27 8.88 9.03 8.84 7.22 5.80 6.73 6.97 9.27 10.06 7.61 2.93 2.70 2.83 0.41 5.90 6.19
Johnson & Johnson 23.92 26.40 29.06 20.51 19.09 23.89 31.49 79.71 141.63 160.27 164.15 125.46 94.27 87.06 73.87 83.07 96.82 81.36 81.56 55.49
Thermo Fisher Scientific Inc. 5.62 5.62 5.53 5.54 5.98 6.64 8.28 11.56 13.59 15.70 16.73 17.49 19.94 19.52 17.58 14.07 10.78 7.93 7.66 7.02

Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Q3 2024 Calculation
Interest coverage = (EBITQ3 2024 + EBITQ2 2024 + EBITQ1 2024 + EBITQ4 2023) ÷ (Interest expenseQ3 2024 + Interest expenseQ2 2024 + Interest expenseQ1 2024 + Interest expenseQ4 2023)
= (1,506,800 + 1,642,900 + 716,800 + 1,165,900) ÷ (13,800 + 14,800 + 16,100 + 18,300) = 79.88

2 Click competitor name to see calculations.

Solvency ratio Description The company
Interest coverage ratio A solvency ratio calculated as EBIT divided by interest payments. Regeneron Pharmaceuticals Inc. interest coverage ratio improved from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024.